Update shared on05 Sep 2025
Fair value Increased 3.21%The uptick in AptarGroup’s consensus price target to $178.43 is primarily driven by a modest increase in its forward P/E multiple, while revenue growth expectations remain stable.
What's in the News
- Held Analyst/Investor Day.
- Completed repurchase of 1,218,494 shares (1.84%) for $187.33 million under the current buyback program.
- Precision nasal drug delivery system featured in breakthrough Alzheimer's study, demonstrating effective targeted brain delivery and potential for personalized therapies; Aptar positioned as a key partner for advanced intranasal drug delivery.
- Launched dual-active material science technology to simultaneously control moisture and oxygen, improving stability and shelf life of sensitive pharmaceuticals and medical devices; expanded offerings for GLP-1 drug products and injectable solutions.
Valuation Changes
Summary of Valuation Changes for AptarGroup
- The Consensus Analyst Price Target has risen slightly from $171.50 to $178.43.
- The Future P/E for AptarGroup has risen slightly from 29.17x to 30.35x.
- The Consensus Revenue Growth forecasts for AptarGroup remained effectively unchanged, at 6.3% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.